Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study aimed to estimate the value of urine prostate specific antigen (uPSA) as a marker for benign prostatic hyperplasia (BPH) but reported no new clinical findings.

This research concludes that finasteride significantly reduces dihydrotestosterone levels and prostate size in men with BPH and may improve urinary symptoms, with greater baseline prostate size predicting more pronounced benefits compared to placebo.

Women with effluvium have higher levels of certain urinary steroids, possibly due to stress and increased adrenal activity.

This case report describes a 23-year-old woman with a history of ambiguous genitalia and complex medical conditions, including a pelvic mass and hirsutism, observed from childhood to adulthood.

This narrative review discusses the potential of urinary bladder matrix as a bio-scaffold in hair restoration but provides no new clinical results or trials; it highlights regenerative technology and suggests further exploration.

This study found that men with early-onset androgenetic alopecia had larger prostate volumes and lower urinary flow rates compared to those without the condition, suggesting a potential link between AGA and urinary symptoms.

This review examines microbial production and applications of gluconic acid, focusing on the enzymatic processes involved, and offers no new experimental results.

This paper discusses risk factors and prevention strategies for acute urinary retention secondary to benign prostatic hyperplasia, emphasizing the role of PSA levels and the benefits of medications like finasteride and alpha-blockers, but reports no new clinical results.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

In this study, short-term treatment with lovastatin showed no effect on symptom severity, prostate volume, or PSA levels in men with prostatic enlargement from presumed benign prostatic hyperplasia.

This review discusses recent advancements and new approvals in the medical treatment of lower urinary tract symptoms, particularly highlighting drugs for nocturia and ongoing trials for multiple related conditions, while reporting no new clinical results.

This review discusses the stratification and management of male patients with lower urinary tract symptoms and benign prostatic hyperplasia in primary care and reports no new clinical results.

This review examines the use of tadalafil and finasteride as a combined therapy for BPH, suggesting it may effectively reduce treatment-related sexual adverse events and improve symptom relief.

This study found that lower urinary tract symptoms were linked to reduced functional ability in older adults, with distinct associations for nocturia in men and frequency, urgency, and overactive bladder in women.

This study found that combining 4 mg doxazosin with 0.2 mg tamsulosin improved urinary symptoms with fewer vasodilatory side effects compared to a higher dose of doxazosin in hypertensive males with LUTS.

This report presents no new clinical results; it discusses the application of ACell MatriStem™, a porcine urinary bladder-derived extracellular matrix, in wound healing.

This study found that patients treated with dutasteride were significantly less likely to experience acute urinary retention and prostate-related surgeries compared to those treated with finasteride.

This review discusses sexual dysfunction as a potential side effect of drugs for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms and reports no new clinical results; it emphasizes the need for methodologically robust studies.

This study found that men aged 60 or older with postoperative urinary retention were more likely to undergo bladder outlet procedures within three years.

This reply argues that children with isolated extraordinary daytime frequency do not require extensive testing or aggressive pharmacologic treatments, noting potential negative effects of oxybutynin.

Taking dutasteride every other day works as well as daily and better preserves sexual function.

This review discusses the efficacy of the lipidosterolic extract of Serenoa repens for treating lower urinary tract symptoms and reports no new clinical results; the authors propose further examination of the existing literature and guidelines.

In this study, the combination of Serenoa repens extract with Phenolmicin P3 and Bosexil suppositories significantly improved lower urinary tract symptoms and decreased PSA levels in patients with benign prostatic obstruction-related symptoms.

This study observed that improving male lower urinary tract symptoms was associated with a lower risk of death, with a 1-point improvement in symptoms leading to a 4% reduction in mortality risk.

This study found no correlation between androgenic alopecia and lower urinary tract symptoms or prostate volume in men who underwent a Green Light Laser Vaporization Procedure of the prostate.

This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.

This randomized, placebo-controlled trial reported that USPlus PRO saw palmetto extract significantly improved lower urinary tract symptoms, including voiding, incomplete emptying, and weak stream, as well as sexual function in males over 12 weeks, while maintaining a favorable safety profile.

This review discusses various treatment options for lower urinary tract symptoms in men, including behavioral, pharmacologic, and surgical interventions, and reports no new clinical results; the authors emphasize first-line therapy with behavioral and pharmacologic approaches.

This study found that among patients over 45 with lower urinary tract symptoms due to benign prostatic hyperplasia, those with androgenic alopecia had worse symptoms and higher testosterone levels than those without baldness.

This study found that tadalafil use was associated with a decreased risk of major adverse cardiac events and venous thromboembolism in men with lower urinary tract symptoms.